Latest Breaking News On - Abbott navitor - Page 1 : vimarsana.com

Royal Stoke patients first in UK to get this treatment

Royal Stoke becomes 'UK first' in 'great news' for heart patients

3 No-Brainer Medical Device Stocks to Buy Right Now

These companies have consistently delivered revenue and EPS gains.

No serious paravalvular leak at 30 days in study of next-generation TAVR system

Abbott (ABT) Says Late-Breaking Data Reinforce Benefits of Minimally Invasive Heart Devices

Data backs Abbott Navitor, Amulet heart implants

Abbott (NYSE:ABT) announced today that studies support its next-generation Navitor TAVI system and its Amplatzer Amulet device.

Abbott Receives FDA Approval for Navitor TAVI System

Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant

Abbott wins FDA nod for Navitor transcatheter aortic valve implant

Abbott (NYSE:ABT) announced today that it received FDA approval for its latest-generation transcatheter aortic valve implant (TAVI) system.

Abbott nabs European approval for Navitor aortic heart valve replacement

May 17, 2021 11:35am The Navitor artificial heart valve is implanted using Abbott’s CE-marked FlexNav delivery device and reduces the blood leaks that often occur after replacement. (Abbott) After Boston Scientific retired its entire line of Lotus Edge replacement heart valves late last year amid a flurry of issues with its delivery system, Abbott has stepped up to fill in the gap in the transcatheter aortic valve replacement market. Abbott’s Navitor TAVR system has received a CE mark, making it available in Europe to those with severe aortic stenosis and a high or extreme risk of complications from surgery. TAVR systems offer a less risky, minimally invasive alternative to open-heart surgery to treat aortic stenosis, where the aortic valve narrows and restricts blood flow out of the left ventricle to the aorta, weakening the heart muscle over time as it s forced to work harder.